Aligos Therapeutics (ALGS) vs IN8bio (INAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
IN8bio (INAB) has outperformed Aligos Therapeutics (ALGS) over the past year, losing 55.4% versus a loss of 86.8%. Over five years, INAB leads with a -99.6% price change compared with -99.7% for ALGS. IN8bio is the larger company by market cap ($8.2 million vs $7.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | INAB |
|---|---|---|
| Share price | $1.22 | $0.758 |
| Market cap | $7.62M | $8.19M |
| 1-day change | -2.40% | -1.86% |
| YTD return | -86.91% | -67.61% |
| 1-year return | -86.75% | -55.41% |
| 5-year return | -99.70% | -99.63% |
| EPS (TTM) | $-6.46 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.19M | — |
| Revenue growth (YoY) | -39.46% | — |
| Net income (latest FY) | $-24.19M | $-19.44M |
| Operating margin | -4024.93% | — |
| Net margin | -1106.72% | — |
| 52-week high | $13.69 | $2.73 |
| 52-week low | $1.18 | $0.724 |
| Distance from 52-week high | -91.09% | -72.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +4193.44% | +823.48% |
| Average volume | 57.37K | 120.61K |
| Shares outstanding | 5.45M | 10.81M |
| Employees | 82 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed ALGS by 31.3 percentage points over the past year.
About Aligos Therapeutics
ALGS stock →Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
ALGS vs INAB FAQ
Which is bigger, Aligos Therapeutics or IN8bio?
IN8bio (INAB) is larger, with a market capitalization of $8.19M compared with $7.62M for Aligos Therapeutics (ALGS).
Which stock has performed better over the past year, ALGS or INAB?
INAB returned -55.41% over the past 12 months, compared with -86.75% for ALGS (price return, excluding dividends). Past performance does not predict future results.
Are Aligos Therapeutics and IN8bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.